Core Viewpoint - Alibaba Health reported a strong financial performance for the first half of the fiscal year 2026, with significant growth in revenue, gross profit, and net profit, while continuing to invest in the medical AI sector to enhance its strategic positioning in the B2B healthcare market [1] Financial Performance - Revenue reached RMB 16.697 billion, representing a year-on-year increase of 17% [1] - Gross profit amounted to RMB 4.184 billion, with a year-on-year growth of 18.4% [1] - Net profit was RMB 1.266 billion, showing a substantial year-on-year increase of 64.7% [1] - Adjusted net profit stood at RMB 1.356 billion, reflecting a year-on-year growth of 38.7% [1] Business Growth and Strategy - The company maintains a robust and high-quality growth trajectory, focusing on enhancing product offerings and user experience to meet increasing health demands [1] - As the largest online B2C healthcare product retail platform in China, Alibaba Health serves over 56,000 merchants on the Tmall Health platform, with SKU growth exceeding 97 million [1] - The platform's GMV has achieved stable year-on-year growth, supported by an increase in active annual users and annual ARPU [1] Operational Efficiency - Alibaba Health's self-operated pharmacy business has significantly improved operational efficiency, leading to enhanced profitability [1] - Business revenue for the self-operated segment reached RMB 14.38 billion, marking an 18.6% year-on-year increase [1] - Active annual users and member ARPU continue to grow, with SKU count increasing by 98.8% to 1.61 million [1]